Volition Presents Early Stage Solid Cancer Detection at ESMO MAP Conference
VolitionRx Limited (NYSE AMERICAN: VNRX) presented new data on its Capture-Seq™ technology for early-stage solid cancer detection during the European Society of Medical Oncology Molecular Analysis for Precision Oncology (ESMO MAP) conference in London. The company reported strong preliminary results, including 100% sensitivity in detecting cancers across two independent cohorts and promising validation from a third cohort with high accuracy in identifying stage I/II cancers. Dr. Andrew Retter highlighted the clinical significance of these findings, emphasizing that if validated at scale, Capture-Seq™ could address an unmet need for multi-cancer early detection (MCED) as well as Minimal Residual Disease (MRD). Dr. Jake Micallef noted methodological advancements in isolating CTCF-protected plasma ctDNA and the potential of this technology to serve both MCED and MRD applications. Volition is advancing Capture-Seq™ through further studies, including evaluations for competing conditions and collaborations with oncology experts.
Topics: cancer detection Capture-Seq™ technology clinical validation ctDNA epigenetics MRD (Minimal Residual Disease)